November 1, 2018 (Vol. 38, No. 19)
A range of recombinant monoclonal antibodies (mAbs) anti-ranibizumab that are highly specific for the mAb drug ranibizumab (Lucentis) or the complex of ranibizumab with its target, vascular endothelial growth factor A (VEGF-A). Ranibizumab is used for the treatment of wet age-related macular degeneration (AMD), a common form of age-related vision loss, and for macular edema and diabetic retinopathy. The anti-ranibizumab antibodies are inhibitory, non-inhibitory, and drug-target complex-specific antibodies and designed for use in pharmacokinetic (PK) and immunogenicity assays for ranibizumab and biosimilars. These anti-idiotypic antibodies are generated using Human Combinatorial Antibody Library (HuCAL®) and CysDisplay®, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures a consistent and secure supply.